Disease-modifying therapy prescription patterns in people with multiple sclerosis by age
Background: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are approved for their ability to reduce disease activity, namely clinical relapses and signal changes on magnetic resonance imaging (MRI). Disease activity appears age dependent. Thus, the greatest benefit would be expected...
Main Authors: | Yinan Zhang, Amber Salter, Shan Jin, William J. Culpepper, Gary R. Cutter, Mitchell Wallin, Olaf Stuve |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-03-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/17562864211006499 |
Similar Items
-
Clinical trials in multiple sclerosis: milestones
by: Yinan Zhang, et al.
Published: (2018-07-01) -
Evolution of clinical trials in multiple sclerosis
by: Yinan Zhang, et al.
Published: (2019-02-01) -
Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
by: Yinan Zhang, et al.
Published: (2020-10-01) -
Clinical trials in multiple sclerosis: potential future trial designs
by: Navid Manouchehri, et al.
Published: (2019-05-01) -
Isoniazid in autoimmunity: a trigger for multiple sclerosis?
by: Bardia Nourbakhsh, et al.
Published: (2014-09-01)